Abstract 26P
Background
As components of the liquid biopsy, Extracellular Vesicles (EVs) have gained major interest as biomarkers of diagnosis, prognosis and prediction of response/resistance therapies. Here we investigated if plasma EV immune profile, size and concentration with plasma proteomics might discriminate responding from non-responding pts affected by UC or VH undergoing CABO+DURVA.
Methods
We evaluated 40 pts for their plasma EV profile at baseline and at the first reassessment. Baseline samples of 50 pts were evaluated for predictive potential. EVs were profiled using modified MACSplex technology coupled with flow cytometry and nanoparticle tracking analysis. Whole plasma was also searched for further indicators of response/resistance by proteomics (92 analytes, Immune-oncology panel, Olink).
Results
Preliminary analysis of EV markers measured in baseline samples evidenced no major association with response, although VH histology (n=13) showed a significant enrichment of CD1c and CD14 expressing EVs. A significant increase of immune markers were detected on-therapy time point (CD14,CD1c,CD2,CD20,CD8 and CD69; EV markers CD9, CD63 and CD81; platelet markers CD29, CD31 and CD326). This was also reflected by the global distribution of EV markers, which evidenced unexpectedly high levels of EVs exposing CD81 EV marker and CD8 already at baseline, with a further increase after therapy initiation. Finally, the dichotomization by response (responders n=21 vs non-responders n=19) highlighted that a statistically significant increase of immune EVs was detectable almost exclusively in responding.
Conclusions
Our preliminary results suggest that the early dynamics in plasma EVs may inform on the clinical outcome to DURVA plus CABO. The significant increase of EVs expressing immune markers measured at first reassessment in responding may derive from the activation of the immune system induced by therapy. The comprehensive analysis of EV profiles, size and concentration together with plasma proteomics could give rise to predictive/prognostic biomarkers of response, especially in pts with non-UC VHs.
Clinical trial identification
NCT03824691.
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
Funding
AIRC IG-25078, NET-2016-02361632 from Italian Health Ministry.
Disclosure
P. Giannatempo: Financial Interests, Personal, Advisory Board: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display